214260.KQ

Strong SellSinker

Raphas Co., Ltd. · Healthcare · South Korea · $52M cap · $53K/day traded

KRW 7,540 +2.4% · close 19 Oct · scored 20 Oct

Sinker: Weak, expensive and falling. Nothing here to keep it afloat.

17
StockRank
Get score and insider alerts
Quality
39
Value
30
Momentum
29

As of 20 Oct 2026, MoatMap's StockRank for Raphas Co., Ltd. (214260.KQ) is 17/100, ranked against 24,000+ stocks in 35 markets (Quality 39, Value 30, Momentum 29, each scored against its sector).

Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →

P/E (TTM)
—
peers 16.1x
ROE
-18.7%
peers -0.0%
D/E
0.9x
peers 0.3x
Dividend %
—
trailing yield

ABOUT RAPHAS CO., LTD.

Read

Raphas Co., Ltd. manufactures and sells biodegradable microneedles in Korea. The company offers skin care, medical device, whitening care, and wrinkle care under the Acropass brand; and health food product under the FitKong brand.

FINANCIAL SUMMARY (KRW)

Year2022202320242025CAGRTTM
Revenue23.6B27.9B27.2B31.0B9.4%30.1B
EPS (KRW)-988.00-1,018-544.00-484.00—-483.30
Shares8.5M8.3M8.4M8.4M-0.6%8.4M
Debt29.4B46.8B30.6B34.1B5.0%26.0B
Equity40.9B29.5B29.4B28.3B-11.5%—
Op CF-3.6B-1.8B4.9B1.4B-70.7%—
Inv CF3.6B4.3B14.1B-2.1B——
Fin CF569.2M9.2B-23.3B1.5B——
Loading 1Y...
PRICE (1Y) · KRW-7.9%
6,9507,2607,5707,8808,1902 Sep23 Sep19 Oct
SMA 50SMA 200

Price checkFinding a floorExperimental

No new 52-week low for 17 weeks, 21% above that low, but not back above a rising 50-day average.

SwingsBumpy

Swung more than 67% of stocks we rank over the past year (53% a year).

How this is worked out

StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.

The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
KRW 7,540
RSI (14)
47.6
52-Week Range-54.8% from high
Low KRW 6,240High KRW 16,670

SCORE BREAKDOWN

Quality
39
ROIC
-3.1%40.3
ROE
-18.7%30.1
GP/Assets
18.1%41.8
Op. Margin
-23.3%23.7
FCF/Assets
0.9%48.2
Piotroski
783.5
Int. Cover
-0.3x34.9
D/E Ratio
0.87x17.0
Current Ratio
0.82x6.4
Value
30
P/E (TTM)
—N/A
EV/EBITDA
-2587.8x25.0
P/FCF
108.6x14.1
P/B
2.2x55.2
P/S
2.1x66.7
Div Yield
0.0%5.7
Momentum
29
52W High %
45%22.0
RS 6M
-21%40.8
SMA 50/200
0.85x21.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$52M
P/E (Forward)
—
Gross Margin
43.4%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 214260.KQ are excluded.

TickerCompanyMkt CapStockRankSignal
214260.KQRaphas Co., Ltd.(you)$52M17Strong Sell
299660.KQCellid, Co., Ltd.$57M16Strong Sell
168330.KQNaturalendo Tech Co., Ltd.$55M22Sell
048530.KQiNtRON Biotechnology, Inc.$64M13Strong Sell
203400.KQABION Inc.$59M25Sell
261780.KQAriBioLab Co.,Ltd.$70M11Strong Sell
308080.KQViGenCell Inc.$87M11Strong Sell
389030.KQGENINUS Inc.$56M1Strong Sell
235980.KQMedPacto, Inc.$71M5Strong Sell
166480.KQCORESTEMCHEMON Inc.$75M6Strong Sell

Peer medians: ROE -0.0% · P/E 16.1x · Gross margin 43.2%

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

Raphas Co., Ltd. (214260.KQ): Stock Score Summary

Raphas Co., Ltd. (214260.KQ) has a MoatMap StockRank of 17/100 based on Quality (39/100), Value (30/100), and Momentum (29/100) factor scores. The current signal is STRONG SELL.

Raphas Co., Ltd. manufactures and sells biodegradable microneedles in Korea. The company offers skin care, medical device, whitening care, and wrinkle care under the Acropass brand; and health food product under the FitKong brand.

Key Financial Metrics

PriceKRW 7,540
Market Cap$52M
Price/Book2.18
Return on Equity-18.7%
Return on Invested Capital-3.1%
Debt/Equity0.87x
Gross Margin43.4%
Operating Margin-23.3%
Revenue Growth-6.6%
Free Cash Flow$482K

Raphas Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is Raphas Co., Ltd.’s (214260.KQ) StockRank?
MoatMap’s StockRank for Raphas Co., Ltd. (214260.KQ) is 17/100, with a Strong Sell signal. It is a composite of Quality (39), Value (30), and Momentum (29), each scored against its sector. The composite is then ranked across MoatMap’s universe of 24,000+ stocks.
Does Raphas Co., Ltd. have an economic moat?
Raphas Co., Ltd. (214260.KQ) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Raphas Co., Ltd. a buy, hold, or sell?
MoatMap’s current signal for Raphas Co., Ltd. (214260.KQ) is Strong Sell, based on a StockRank of 17/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Raphas Co., Ltd. in?
Raphas Co., Ltd. (214260.KQ) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).